CVSICVSI
I think this Stock will pump so hard will melt faces
I'm buying now and around 0.10
Kindly dollar cost your investment
Good luck
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0151 USD
3.10 M USD
16.00 M USD
184.23 M
About CV Sciences, Inc.
Sector
CEO
Joseph D. Dowling
Headquarters
San Diego
Website
Founded
2010
FIGI
BBG0022J68R8
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the following segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment focuses on developing cannabinoids to treat medical indications. The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, CA.
CV Science can make you highCVSI seems to have bottomed out and offers a good risk/reward ratio.
CV Science is a Cannabidiol (CBD) producer and its product is the #1 selling natural hemp extract in the USA.
Keep in mind that this is an OTC stock.
$CVSI CV Sciences, Inc. 30% Upside CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol product
$CVSI Flashing Signs of Potential Bottom?CVSI had a brutal last year, but is fighting for fresh support and just broke the longstanding bear trendline suggesting that a turnaround could be in the cards.
-----------------------------
CV Sciences Inc (OTCMKTS:CVSI)
CV Sciences bills itself as a company that operates two distinct business
CV Sciences, Inc On watchlist for reversal opportunity CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol product
CV Science a good risk reward tradeEntry level $2.50 with stop loss $2.15 = Profit target $4.00
Average Analysts recommendation = buy with a $6.33 price target.
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharma
$CVSI Forming A V Bottom$CVSI has been beaten up along with the rest of the cannabis sector.
Recent price action indicates that the low might be in as the critical $1.55 support level held.
Next major resistance level is $3. Those that want to go Long can buy with a stop below $1.55 and add to the position on a break abo
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CVSI is 0.0385 USD — it has decreased by −13.48% in the past 24 hours. Watch CV Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange CV Sciences, Inc. stocks are traded under the ticker CVSI.
CVSI stock has fallen by −3.99% compared to the previous week, the month change is a −11.90% fall, over the last year CV Sciences, Inc. has showed a 18.46% increase.
CVSI reached its all-time high on Feb 21, 2014 with the price of 201.0000 USD, and its all-time low was 0.0263 USD and was reached on Dec 29, 2022. View more price dynamics on CVSI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CVSI stock is 34.90% volatile and has beta coefficient of −0.07. Track CV Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is CV Sciences, Inc. there?
Today CV Sciences, Inc. has the market capitalization of 7.09 M, it has increased by 5.45% over the last week.
Yes, you can track CV Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
CV Sciences, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
CVSI net income for the last quarter is −456.00 K USD, while the quarter before that showed −584.00 K USD of net income which accounts for 21.92% change. Track more CV Sciences, Inc. financial stats to get the full picture.
No, CVSI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 43.00 employees. See our rating of the largest employees — is CV Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CV Sciences, Inc. EBITDA is −1.78 M USD, and current EBITDA margin is −13.90%. See more stats in CV Sciences, Inc. financial statements.
Like other stocks, CVSI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CV Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CV Sciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CV Sciences, Inc. stock shows the strong sell signal. See more of CV Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.